Sulindac inhibits bumetanide-induced sodium and water excretion.
In an open-label pilot study, we investigated the effect of sulindac on bumetanide-induced diuresis. Nine healthy volunteers were placed on diets with a standard sodium and potassium content. Each volunteer received 1 mg bumetanide orally, and blood and urine samples were collected during an 8-hour period. Urinary losses were replaced isovolumetrically with intravenous normal saline solution. Creatinine clearance and sodium and potassium excretion were compared with and without sulindac pretreatment (200 mg administered orally b.i.d. for 5 days). Sulindac pretreatment resulted in a 22% decrease in the mean cumulative sodium excretion after 3 hours (p less than 0.05) and a 21% decrease in the mean urine flow rate after 2 hours (p less than 0.05). The results suggest that sulindac has an effect on the kidney similar to that of other nonsteroidal agents.
Skinner
M H
MH
Max Samter Institute of Allergy and Clinical Immunology, Chicago, Ill.
Mutterperl
R
R
Zeitz
H J
HJ
D000293:Adolescent; D000328:Adult; D002034:Bumetanide / Q000037:antagonists & inhibitors*; D003404:Creatinine / Q000032:analysis; D003864:Depression, Chemical; D004231:Diuresis / Q000187:drug effects*; D004232:Diuretics / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D007192:Indenes / Q000494:pharmacology*; D008297:Male; D009318:Natriuresis / Q000187:drug effects*; D011188:Potassium / Q000032:analysis; D012964:Sodium / Q000032:analysis; D013467:Sulindac / Q000494:pharmacology*; D013997:Time Factors
D004232:Diuretics; D007192:Indenes; D002034:Bumetanide; D013467:Sulindac; D012964:Sodium; D003404:Creatinine; D011188:Potassium